Business Context and Reporting Period
Company: PMGC Holdings Inc. (Nasdaq: ELAB)
Filing Type: Form 8-K (Current Report)
Date of Report: August 27, 2026 (Events reported through September 2, 2026)
Business Overview: The Company, through its wholly owned subsidiary NorthStrive Biosciences Inc., operates in the biotechnology sector focusing on AI-driven drug discovery. This filing reports a material amendment to a development agreement and a corporate governance change regarding authorized share capital.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing focuses exclusively on material agreements and corporate structural changes.
Material Changes and Agreements
Amendment to License Agreement (Item 1.01)
On August 27, 2026, NorthStrive Biosciences entered into the First Amendment to its Development and License Agreement with Yuva Biosciences, Inc. ("YuvaBio"). Key changes include:
- Expansion Program: Formalized a three-phase expansion program to advance four AI-discovered compounds toward lead compound nomination.
- AI Development Program (AIDP): Defined a three-phase process: Phase I (therapeutic potential assessment), Phase II (virtual screening of candidate compounds), and Phase III (biological validation).
- Field of Use: Defined the "Northstrive Field of Use" as "Cardiac Diseases" and "Obesity."
- Intellectual Property: Added definitions for "AI Results" (up to four compounds upregulating ANT) and "YuvaBio Platform Technology," covering MitoNova software, algorithms, datasets, and mitochondrial biology platforms.
Amendment to Articles of Incorporation (Item 5.03)
On August 31, 2026, the Company filed a Certificate of Amendment with the State of Nevada to increase its authorized capital stock:
- Total Authorized Shares: Increased to 1,500,000,000 shares.
- Common Stock: 1,000,000,000 shares authorized (par value $0.0001).
- Preferred Stock: 500,000,000 shares authorized (par value $0.0001).
- Approval: Approved by holders representing 60.34% of voting power.
Guidance, Outlook, and Risks
Outlook: Management has initiated a structured three-phase expansion program to validate AI-discovered compounds for cardiac and obesity indications. The filing references a press release dated September 1, 2026, detailing these terms.
Risks and Contingencies: The filing does not explicitly list new risks. However, the success of the business strategy is contingent upon the successful execution of the AI Development Program and the biological validation of the identified compounds by YuvaBio.
Investor Verification Checklist
- Verify the specific financial terms (milestone payments, royalties) of the Amended License Agreement with YuvaBio, which are referenced but not detailed in the text of this 8-K.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) to confirm any additional provisions regarding the new preferred stock class.
- Examine the press release (Exhibit 99.1) for further details on the timeline and specific targets of the three-phase expansion program.
- Confirm the current outstanding share count to assess the dilution potential of the newly authorized 1 billion common shares.